Arbutus Biopharma (ABUS) Income from Continuing Operations (2013 - 2026)
Arbutus Biopharma (ABUS) posted Income from Continuing Operations of 169700000.0 for Q1 2026, up 3929.84% sequentially from 4431000.0 in Q4 2025, and up 791.81% YoY from 19028803.25 in Q1 2025.
Arbutus Biopharma (ABUS) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Income from Continuing Operations for 14 years, with the latest figure at 169700000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 791.81% year-over-year to 169700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 160041000.0 (up 307.63% YoY) and the FY2025 annual result came in at 215482000.0, down 208.18% from the prior year.
- Income from Continuing Operations grew to 169700000.0 in Q1 2026 per ABUS's latest filing, from 4431000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 169700000.0 in Q1 2026 and troughed at 24530000.0 in Q1 2025.
- A 5-year average of 4548882.35 and a median of 17094000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations sank 36.38% in 2025, then soared 791.81% in 2026.
- Over 5 years, Income from Continuing Operations stood at 21932000.0 in 2022, then grew by 11.95% to 19312000.0 in 2023, then surged by 32.8% to 12978000.0 in 2024, then soared by 65.86% to 4431000.0 in 2025, then jumped by 3929.84% to 169700000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 169700000.0, 4431000.0, and 7730000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -5.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.18 Mn |
| Mar 31, 2026 | 169.70 Mn |
| Dec 31, 2025 | -4.43 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -12.98 Mn |
| Sep 30, 2024 | -19.72 Mn |
| Jun 30, 2024 | -19.85 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -19.31 Mn |
| Sep 30, 2023 | -20.10 Mn |
| Jun 30, 2023 | -17.09 Mn |
| Mar 31, 2023 | -16.34 Mn |
| Dec 31, 2022 | -21.93 Mn |
| Sep 30, 2022 | -17.57 Mn |
| Jun 30, 2022 | -14.19 Mn |
| Mar 31, 2022 | -15.77 Mn |
| Dec 31, 2021 | -21.32 Mn |
| Sep 30, 2021 | -19.16 Mn |